## Travis E Grotz

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6105641/publications.pdf

Version: 2024-02-01

257357 360920 1,648 86 24 35 h-index citations g-index papers 86 86 86 2251 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2022, 26, 414-424.	0.9	3
2	Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 1579-1591.	0.7	29
3	ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 1594-1595.	0.7	O
4	What is the Risk for Peritoneal Metastases and Survival Afterwards in T4 Colon Cancers?. Annals of Surgical Oncology, 2022, 29, 4224-4233.	0.7	4
5	"Answers in hours― A prospective clinical study using nanopore sequencing for bile duct cultures. Surgery, 2022, 171, 693-702.	1.0	12
6	ASO Visual Abstract: What is the Risk for Peritoneal Metastases and Survival Afterwards in T4 Colon Cancers?. Annals of Surgical Oncology, 2022, , 1.	0.7	1
7	Is CRS-HIPEC Still Indicated in Patients With Extraperitoneal Disease?. Journal of Surgical Research, 2022, 277, 269-278.	0.8	O
8	Development and Validation of an Explainable Machine Learning Model for Major Complications After Cytoreductive Surgery. JAMA Network Open, 2022, 5, e2212930.	2.8	13
9	A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. Journal of Surgical Oncology, 2021, 123, 187-195.	0.8	4
10	A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surgical Oncology, 2021, 37, 101492.	0.8	15
11	Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. Annals of Surgical Oncology, 2021, 28, 4499-4507.	0.7	10
12	The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2021, 25, 2908-2919.	0.9	4
13	Can cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) be diagnosed in a patient with non-steroidal anti-inflammatory drug exposure?. BMJ Case Reports, 2021, 14, e238160.	0.2	3
14	Surgical Management of Metastatic Gastrointestinal Stromal Tumors. Current Treatment Options in Oncology, 2021, 22, 37.	1.3	4
15	Finding the Balance: General Surgery Resident Versus Fellow Training and Exposure in Hepatobiliary and Pancreatic Surgery. Journal of Surgical Education, 2021, 78, 875-884.	1.2	3
16	Perception versus reality: A National Cohort Analysis of the surgeryâ€first approach for resectable pancreatic cancer. Cancer Medicine, 2021, 10, 5925-5935.	1.3	3
17	Intraoperative bile duct cultures in patients undergoing pancreatic head resection: Prospective comparison of bile duct swab versus bile duct aspiration. Surgery, 2021, 170, 1794-1798.	1.0	2
18	Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study. Journal of Cancer Epidemiology, 2021, 2021, 1-6.	0.5	6

#	Article	IF	CITATIONS
19	Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 134-146.	0.7	14
20	Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2020, 24, 155-164.	0.9	27
21	Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 156-164.	0.7	13
22	Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. Annals of Surgical Oncology, 2020, 27, 783-792.	0.7	20
23	Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. American Journal of Surgery, 2020, 219, 478-483.	0.9	39
24	Preoperative opioid use is associated with increased length of stay after pancreaticoduodenectomy. Hpb, 2020, 22, 1074-1081.	0.1	4
25	Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study. Journal of Gastrointestinal Surgery, 2020, 24, 165-176.	0.9	26
26	Integrated cancer networks improve compliance with national guidelines and outcomes for resectable gastric cancer. Cancer, 2020, 126, 1283-1294.	2.0	26
27	CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 4996-5004.	0.7	8
28	Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 4980-4995.	0.7	15
29	Emergent pancreatectomy for neoplastic disease: outcomes analysis of 534 ACS-NSQIP patients. BMC Surgery, 2020, 20, 169.	0.6	8
30	Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Surgical Research, 2020, 255, 475-485.	0.8	5
31	The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. International Journal of Hyperthermia, 2020, 37, 1182-1188.	1.1	5
32	The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. Annals of Surgical Oncology, 2020, 27, 4894-4907.	0.7	11
33	Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review. Journal of Clinical Medicine, 2020, 9, 748.	1.0	22
34	Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. Journal of Surgical Oncology, 2020, 122, 980-985.	0.8	10
35	What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative. Clinical Colorectal Cancer, 2020, 19, e1-e7.	1.0	14
36	Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Surgery, 2020, 167, 803-811.	1.0	32

#	Article	IF	CITATIONS
37	Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. Annals of Surgical Oncology, 2020, 27, 4883-4891.	0.7	11
38	Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World Journal of Gastrointestinal Oncology, 2020, 12, 756-767.	0.8	21
39	Robotic-assisted cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Journal of Robotic Surgery, 2019, 13, 175-179.	1.0	7
40	Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery, 2019, 166, 547-555.	1.0	72
41	Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Annals of Surgical Oncology, 2019, 26, 2234-2240.	0.7	16
42	Mucinous appendiceal neoplasms: classification, imaging, and HIPEC. Abdominal Radiology, 2019, 44, 1686-1702.	1.0	25
43	Advancements and challenges in treating advanced gastric cancer in the West. World Journal of Gastrointestinal Oncology, 2019, 11, 652-664.	0.8	25
44	Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients. Surgical Oncology, 2018, 27, 11-17.	0.8	48
45	Elevated brain natriuretic peptide (BNP) is an early marker for patients at risk for complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). Journal of Surgical Oncology, 2018, 117, 685-691.	0.8	6
46	Radiation Therapy for Retroperitoneal Sarcomas: Influences of Histology, Grade, and Size. Sarcoma, 2018, 2018, 1-8.	0.7	12
47	Patient Selection for Cytoreductive Surgery. Surgical Oncology Clinics of North America, 2018, 27, 443-462.	0.6	7
48	Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World Journal of Gastrointestinal Oncology, 2018, 10, 282-289.	0.8	12
49	Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND). Annals of Surgery, 2017, 265, 192-196.	2.1	39
50	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Annals of Surgical Oncology, 2017, 24, 2646-2654.	0.7	30
51	Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial. Journal of the American College of Surgeons, 2016, 222, 253-260.	0.2	16
52	Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 2914-2919.	0.7	13
53	Frozen section analysis of SLNs in trunk and extremity melanoma has a high false negative rate but can spare some patients a second operation. Journal of Surgical Oncology, 2016, 114, 879-883.	0.8	4
54	The Prognostic Role of the Preoperative Absolute Lymphocyte Count and Absolute Monocyte Count in Patients With Resected Advanced Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 252-258.	0.6	26

#	Article	IF	CITATIONS
55	A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma. Melanoma Research, 2015, 25, 406-411.	0.6	20
56	Intussusception in adults and the role of evolving computed tomography technology. American Journal of Surgery, 2015, 209, 580-583.	0.9	24
57	Management of regional lymph nodes in the elderly melanoma patient: Patient selection, accuracy and prognostic implications. European Journal of Surgical Oncology, 2015, 41, 157-164.	0.5	11
58	Negative Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma is Associated with a Low Risk of Same-Nodal-Basin Recurrences. Annals of Surgical Oncology, 2015, 22, 4060-4066.	0.7	39
59	The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma. Melanoma Research, 2015, 25, 157-163.	0.6	31
60	Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. Oncolmmunology, 2015, 4, e1026504.	2.1	25
61	Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. Journal of Human Genetics, 2014, 59, 124-128.	1.1	31
62	Rare Presentations of Primary Melanoma and Special Populations. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 635-641.	0.6	30
63	Adjuvant GM-CSF Improves Survival in High-risk Stage IIIC Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 467-472.	0.6	26
64	Recurrence patterns following a negative sentinel lymph node biopsy (SLNB) for Merkel cell carcinoma (MCC). Journal of the American College of Surgeons, 2014, 219, e174.	0.2	0
65	Preservation of the deep muscular fascia and locoregional control in melanoma. Surgery, 2013, 153, 535-541.	1.0	20
66	Prognostic factors in Merkel cell carcinoma: Analysis of 240 cases. Journal of the American Academy of Dermatology, 2013, 68, 425-432.	0.6	155
67	Minimally Invasive Inguinal Lymph Node Dissection (MILND) for Melanoma: Experience from Two Academic Centers. Annals of Surgical Oncology, 2013, 20, 340-345.	0.7	34
68	Limitations of Lymph Node Ratio, Evidence-Based Benchmarks, and the Importance of a Thorough Lymph Node Dissection in Melanoma. Annals of Surgical Oncology, 2013, 20, 4370-4377.	0.7	26
69	Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes. Melanoma Research, 2013, 23, 132-137.	0.6	24
70	Abstract 1266: Immune cell profile of the SLN has prognostic value in stage III melanoma , 2013, , .		0
71	Abstract A135: ConcurrentMCL1andJUNamplification in pseudomyxoma peritonei, 2013,,.		0
72	Regional lymphatic immunity in melanoma. Melanoma Research, 2012, 22, 9-18.	0.6	18

#	Article	IF	CITATIONS
73	Natural History of Merkel Cell Carcinoma Following Locoregional Recurrence. Annals of Surgical Oncology, 2012, 19, 2556-2562.	0.7	17
74	Sentinel Lymph Node Biopsy in Multicentric Breast Cancer: Five-Year Results in a Large Series from a Single Institution. Breast Diseases, 2012, 23, 174-176.	0.0	0
75	Is There Still a Role for Axillary Dissection in Breast Cancer Surgery?. Current Breast Cancer Reports, 2012, 4, 110-118.	0.5	0
76	Adult Intussusception in the Last 25 Years of Modern Imaging: Is Surgery Still Indicated. Gastroenterology, 2011, 140, S-1011.	0.6	0
77	Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Modern Pathology, 2011, 24, 487-494.	2.9	51
78	Mayo Clinic Consensus Recommendations for the Depth of Excision in Primary Cutaneous Melanoma. Mayo Clinic Proceedings, 2011, 86, 522-528.	1.4	26
79	Adult Intussusception in the Last 25ÂYears of Modern Imaging: Is Surgery Still Indicated?. Journal of Gastrointestinal Surgery, 2011, 15, 1699-1705.	0.9	61
80	Surveillance strategies for gastrointestinal stromal tumors. Journal of Surgical Oncology, 2011, 104, 921-927.	0.8	30
81	The dynamic human immune response to cancer: it might just be rocket science. Immunotherapy, 2011, 3, 1021-1024.	1.0	7
82	In-transit melanoma: an individualized approach. Oncology, 2011, 25, 1340-8.	0.4	19
83	Is There a Role for Endoscopic Therapy as a Definitive Treatment for Post-Laparoscopic Bile Duct Injuries?. Journal of the American College of Surgeons, 2010, 211, 495-502.	0.2	26
84	Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option?. Hpb, 2010, 12, 546-553.	0.1	87
85	Pyogenic liver abscess secondary to Streptococcus anginosus in an adolescent. Journal of Pediatric Surgery, 2010, 45, e15-e17.	0.8	5
86	Can We Predict Surgical Futility/Cure in Gallbladder Cancer?. Annals of Surgical Oncology, 0, , .	0.7	0